Pharmaceuticals
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered inBuenos Aires, Argentina, with decades of experience in ...
2025-11-26 09:06
2668
Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with canc...
2025-11-25 23:06
2038
BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan
XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co...
2025-11-25 22:41
3771
Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
* Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization. * Integrated setup drives strong client demand and a record order-intake level in 2025. * End-to-end EPC/EPCM delivery from feasibility to qualified handover across key lif...
2025-11-25 18:00
2667
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-11-25 17:00
2677
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization
* The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platf...
2025-11-25 00:30
2993
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
* Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) * BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy...
2025-11-24 23:34
3001
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public inItaly. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon FLORENCE, Italy, Nov. 24, 2025 /PRNewswire/ -- Ten international talents, differing in both...
2025-11-24 22:40
2519
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tiru...
2025-11-24 20:00
2961
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
* Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a favourable safety profile, and real-world public h...
2025-11-24 16:55
2765
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...
2025-11-24 15:11
1948
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an u...
2025-11-24 08:01
2755
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- G...
2025-11-24 08:00
2707
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 20:28
3149
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 06:32
3292
Global Health Leaders Convene in Kuala Lumpur from 25-27 November for Malaysia International Healthcare Megatrends 2025
A Major Conference on Innovation, Digital Health and Sustainable Care Systems KUALA LUMPUR, Malaysia, Nov. 22, 2025 /PRNewswire/ -- Healthcare leaders, policymakers and innovators from around the world will convene inMalaysia next week for the Malaysia International Healthcare (MIH) Megatrends 20...
2025-11-22 02:05
5198
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. * Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufact...
2025-11-21 21:00
4210
Hong Kong hosts landmark International Genomic Medicine Symposium
300 Industry Leaders Gather to Drive Medical Innovations and Showcase Hong Kong's Strengths HONG KONG, Nov. 21, 2025 /PRNewswire/ -- The International Genomic Medicine Symposium (Symposium), jointly organised by the Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The La...
2025-11-21 15:49
2134
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
4299
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
1803
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52348
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51309
